Possible Interaction: Glucose and Glimepiride

“Fasting plasma insulin (66 +/- 18 vs. 84 +/- 48 pmol/l, P = 0.05), and first-phase (19 +/- 8 vs. 32 +/- 11 pmol/l, P = 0.04) and second-phase incremental insulin responses to glucose (48 +/- 23 vs. 72 +/- 32 pmol/l, P = 0.02) improved with glimepiride therapy.”

“ Fasting glucose decreased with both glimepiride and sitagliptin compared with placebo (P = 0.002).”

“ Glimepiride reduces glucose levels blood by stimulating insulin release from functional pancreatic beta cells in response to glucose.”

“There was a significant increase in the rate of glucose infusion necessary to maintain euglycemia during infusion of glimepiride during the low- (12.2 +/- 1.1 vs. 16.1 +/- 1.7 micro mol.”

“In addition, we found that high glucose condition enhanced Aβ40 production and glimepiride significantly decreased high glucose-induced Aβ40 production.”

“It is concluded that glimepiride increases cardiac glucose uptake by an insulin-independent pathway most probably involving an increased protein expression of GLUT1 and GLUT4.”

“Incubation of the cells with either insulin (0.1-30 nM) or the sulfonylurea, glimepiride (0.5-20 microM), in the presence of glucose led to conversion of up to 35 and 20%, respectively, of the total amphiphilic LPL and Gce1 to their hydrophilic versions.”

“In perifused pancreatic islets from euglycemic rats, the secretory response to either glibenclamide or glimepiride (1.0 microM each) increases as a function of the concentration of D-glucose (2.8-16.7 mM) present in the perifusion medium.”

“The integrated, meal-stimulated rise in glucose was lower with glimepiride , but not glibenclamide, compared with placebo [P: 588.1 (372.2) mmol/L·min, glimepiride: 443.0 (346.9) mmol/L·min; p = 0.010, glibenclamide: 586.4 (366.2) mmol/L·min; p = 0.630].”